Hiring company: Pfizer
Role Summary - Sr. Director, Hemophilia Gene Therapy Global Marketing Lead
Pfizer Rare Disease has a robust pipeline with 4 potential launches within the next 3 years. The Rare Disease Hemophilia pipeline includes 3 new transformative, breakthrough hemophilia agents – Hemophilia A Gene Therapy (GTx), Hemophilia B Gene Therapy, and a subcutaneously delivered monoclonal antibody to treat hemophilia A & B (marstacimab). All these products represent significant therapeutic benefits to patients offering breakthrough innovations that address today’s high burden of treatment.
The Sr. Director, Hemophilia Gene Therapy Global Marketing Lead role will need to prepare Pfizer for the launch and commercialization of the FidaVec (Hemophilia B GTx) and the GiroctoVec (Hemophilia A GTx) programs. Both gene therapy programs are in similar late stages of development (P3) and could potentially be Pfizer’s first entrée into the GTx space. Consequently, these launches will have implications and learnings for all future Pfizer GTx launches.
The global Hemophilia community encompass a complex set of stakeholders, engaged end-to-end, from discovery through policy shaping for patient access. Given the transformative nature of these programs and the very competitive nature of the hemophilia marketplace, we need to prepare both the internal Pfizer and external Hemophilia community for great change. Therefore, we must build our capabilities accordingly. Key strategic pillars for ensuring a successful launch are:
- Elucidate the unmet need and build confidence in GTx
- Differentiate Pfizer offerings from competition
- Lead the development of a new Hemophilia Infrastructure of Care to support GTx
- Ensure ability to measure treatment outcomes and ensure patient access
The Sr. Director, Hemophilia Gene Therapy Global Marketing Lead will report to the Global Rare Hematology Portfolio Lead and collaborate closely with the marstacimab team and a team of professionals with specific responsibilities for hemophilia gene therapy marketing including: HCP marketing, Patient marketing, Market Development, Launch Readiness (Go-To-Market) & Launch Excellence (LEx).
The Hemophilia Gene Therapy lead will be responsible for developing and executing a successful launch strategy which includes developing brand strategy, positioning, and messaging. As the leader of the GLocal Launch Team (GLT) for hemophilia gene therapy, the successful candidate will work closely with markets to ensure launch readiness and global consistency. Further, the global hemophilia gene therapy lead will support local markets via the GLocal process and oversee operational elements for launch readiness including packaging, trademark, and other key launch components. Additionally, as the commercial GMT representative, the Hem GTx Lead will partner with Global Regulatory, Global Product Development (GPD), and Global Medical to prepare GiroctoVec and FidaVec for launch and future advancement in lifecycle (including data and label).
The successful candidate must be a strategic thinker with proven operational and execution capabilities who is constantly challenging the status quo to identify ways to drive faster, broader patient impact. The ideal candidate will also have a demonstrated track record of leading in an environment of great complexity and ambiguity.
Collaboration evidenced through Leadership at Every Level will be another attribute of the successful candidate. Demonstrated expertise and capabilities in matrix, cross-functional leadership, and direct leadership experience will be attributes of the successful candidate; engagement in working with Sr. Executives across Businesses (e.g., Regional Presidents and Country Leads) and with cross functional global and local line functions (e.g., Regulatory, Chief Business Office, Corporate Affairs) is a prerequisite.
Roles and Responsibilities
Drive FidaVec and GiroctoVec launch strategy
- Lead the hemophilia GLocal Launch Team (GLT) and drive GLocal commercial efforts for global launch success.
- Represent the commercial point of view to inform development decisions via the Global Medicine Teams (GMT).
- Lead and provide key commercial input/insights into all cross-functional workstreams, including value proposition development, manufacturing strategy, regulatory filing and launch strategy
- Develop fully integrated launch/commercialization plan for FidaVec and GiroctoVec
- Collaborate with cross-functional leads (medical, regulatory, manufacturing, pricing/access) to ensure launch readiness.
- Lead the Hemophilia GTx portfolio Long Range Forecast (LRF) process
- Conduct all activities and make decisions that are in accordance with Company policies &SOPs, Pfizer Values & global regulatory guidelines.
Lead FidaVec and GiroctoVec’s brand strategy, planning, and execution
- Develop and refine FidaVec and GiroctoVec’s brand strategy.
- Lead the development of FidaVec and GiroctoVec’s brand positioning (including co-positioning with marstacimab).
- Ensure coordination of marketing activities at the regional and local level and ensure consistency of approach and implementation.
- Develop and maintain strong relationships with all key functions and countries, including clinical development, medical, clinical operations, manufacturing, legal, finance, regulatory and market research.
- Jointly, with other functions, establish and maintain the appropriate external therapy area network for Pfizer, including, key opinion leaders (KOLs) and other stakeholders to enrich our views.
- Lead annual operating and tactical plan for the Hemophilia GTx portfolio.
- Manage A&P budget for Hemophilia GTx Portfolio.
- Serve as the Hemophilia GTx global lead for the GLocal model and ensure effective mechanisms are in place for co-creation and best practice sharing.
- Provide leadership and guidance into the following marketing areas: HCP, Patient, Launch Operations and Readiness, Market Development, and Infrastructure of Care development.
Champion digital innovation and strategy and launch excellence
- Ideate solutions and support team’s efforts in contributing to a “100% error-free, frictionless patient experience”.
- Evaluation and development of innovative and potentially novel monitoring solutions, including biomarkers.
- Ensure best practices are supported as a part of the Launch Navigation Group (LNG) and Bold Move 3.3 Initiative.
- Set and deliver aspirational objectives to ensure launch readiness.
- Identify, develop, and ensure optimal roll-out of global marketing platforms, capabilities, and competencies
Qualifications
- The candidate must be a self-starter who is able to focus AND multitask in a fast-paced and dynamic environment and support the team through key strategic decisions for Pfizer’s rare disease portfolio as well as able to understand the operational complexities required to execute against GLocal Launch Readiness for a breakthrough medicine in a mature market.
- 15+ years of experience in EU or US and global pharmaceutical marketing or commercial functions.
- BA/BS - degree required. MBA or Advanced degree preferred.
- Substantial brand planning / brand strategy development experience.
- Experience in Rare Disease preferred.
- Prior global launch experience.
- Track record of creating an atmosphere of inclusion, empowering teams, developing colleagues at all levels, driving performance, accelerating decision-making and prioritization that supports strong contribution and engagement.
- Excellent communication and presentation skills, including strong presence with internal and external senior leaders.
- Achieves results through others across functions, geographies, and a variety of personality styles.
- Visionary leader, proven track record of driving change.
- Demonstrated learning agility and comfort with ambiguity, and complex “white space” environments.
Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
Other Job Details
- Last Date to Apply for the job: January 26, 2022
- #LI-PFE
Pfizer requires all U.S. new hires to be fully vaccinated for COVID-19 prior to the first date of employment. As required by applicable law, Pfizer will consider requests for Reasonable Accommodations.
Sunshine Act
Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider’s name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.
EEO & Employment Eligibility
Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.